Study of the Highly-selective RET Inhibitor, BLU667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-6671101) 18164
Study of the Highly-selective RET Inhibitor, BLU667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-6671101) 18164
Trial Category:
Other Solid Tumor
Phase
I
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
